Medicover AB (publ) (MCVEY) Stock

About Medicover AB (publ)

Medicover AB (publ), established in Stockholm, Sweden in 1995, operates as a comprehensive provider of healthcare and diagnostic services throughout a dozen countries, including Germany, Sweden, Poland, Turkey, Belarus, Bulgaria, Georgia, Hungary, Serbia, Moldova, Ukraine, and India. The company's operations are distinctly categorized into two segments: Healthcare Services and Diagnostic Services. Within its Diagnostic Services arm, Medicover performs an extensive array of laboratory analyses. These span various specialties, encompassing tests for allergies and autoimmune conditions, infectious agents (bacteriology, parasitology, microbiology), biochemical and immunological markers, blood grouping and transfusion requirements, tumor detection, clinical chemistry, cellular and tissue pathology (cytology, haematology, histopathology), human genetics, hygiene, molecular biology, and pharmacological/toxicological screenings. This substantial diagnostic infrastructure includes 97 clinical laboratories, 733 blood collection points, and 26 specialized clinics, operational across 10 of its countries of presence. Complementing this, the Healthcare Services division features a broad network comprising 117 medical clinics, 20 fertility centers, 52 dental practices, 25 hospitals, and 25 fitness facilities. Medicover caters to a diverse clientele, serving corporate clients, private individuals, direct patients, and public sector payers.

Medicover AB (publ) is headquartered in SE.

Medicover AB (publ) (MCVEY) stock trades at $16.55 with a market capitalization of $2.50B. The stock is valued at a price-to-earnings (P/E) ratio of 42.01, price-to-book of 6.65, price-to-sales of 1.44. Over the past 52 weeks the stock has ranged between $16.55 and $21.54, and currently trades 23.2% below its 52-week high. It pays a dividend yielding 0.83%.

On profitability, Medicover AB (publ) generates a return on equity (ROE) of 16.01%, above the typical market range of roughly 12-15%, return on capital employed of 11.99%, an operating margin of 7.13%, a net profit margin of 3.44%.

Official website: www.medicover.com

Medicover AB (publ) by the numbers, 2016–2025

Between 2016 and 2025 Medicover AB (publ) reported revenue of $497.0M rising to $2.4B, a change of +378.5% across 10 years. Compounded, revenue has grown 19.0% a year over five years, 16.3% over three, 13.7% over the last twelve months. Net profit rose to $78.0M.

Operating margin went from 3.5% in 2016 to 6.5% in 2025, a gain of 3.0 percentage points. The most recent net margin is 3.44%. On a trailing twelve-month basis to Jun '26, revenue is $2.5B and net profit $85.0M.

Borrowings rose from $211.0M to $1.4B, cash on hand is $92.7M, cash from operations was $344.0M in the latest year, positive in 10 of the last 10.

Return on equity has averaged 8.8% over five years, and was 14.6% in the most recent year.

The share price itself has compounded at —% a year over five years, 1.1% over three, 1.4% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Medicover AB (publ) (MCVEY) — frequently asked questions